 Boston Globe | India rejects plea against cancer drug Boston Globe Last year, India's patent office allowed local drug manufacturer Natco Pharma Ltd. to produce a generic version of Bayer's kidney and liver cancer drug Nexavar on the grounds it would make the drug available to the public at a reasonably affordable price. Enter compulsory licensing Indian patent appeal board upholds compulsory license on Bayer's Nexavar IPAB rejects Bayer's appeal on the grant of Compulsory License |
